Lung cancer trials in Spain

In Spain 273 Also abroad 2733

273 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Where
Madrid
Age
18 years and over
People
130 worldwide
Run by
Sairopa B.V.
See details and how to joinNCT05856981
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
A Coruña, Barcelona, Jerez de la Frontera, Madrid, Málaga, Pozuelo de Alarcón, Santa Cruz de Tenerife, Sevilla, Valencia
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 1/2Taking people
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Where
Barcelona, Girona, Huelva, Logrono, Madrid, Majadahonda, Pamplona, Pozuelo de Alarcón, Toledo
Age
18 years and over
People
334 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01
Phase 2Taking people
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Barcelona, Jerez de la Frontera, Madrid, Santiago de Compostela, Valencia
Age
18 years and over
People
480 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00
Phase 2Taking people
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Where
Madrid, Pamplona, Santiago de Compostela, Valencia
Age
18 years and over
People
130 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00
No phaseTaking people
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Where
A Coruña, Burgos, Córdoba, Jerez de la Frontera, Lugo, Málaga, Ourense, Palma de Mallorca, Santiago de Compostela, Seville, Valladolid, Vigo
Age
18 years and over
People
380 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07230691
Phase 2Taking people
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Where
A Coruña, Badalona, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Logrono, Madrid, Málaga, Pamplona, Valencia
Age
18 years and over
People
240 worldwide
Run by
Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00
Phase 2/3Taking people
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Badalona, Barcelona, Castello De La Plana, Girona, Jerez de la Frontera, Madrid, Málaga, Manresa, Ourense, Palma, Zaragoza
Age
18 years and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
Phase 2Taking people
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Where
Alicante, Barcelona, Madrid
Age
18 years and over
People
68 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07586202
Phase 2/3Taking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
A Coruna, Badajoz, Badalona, Barcelona, Castello De La Plana, Las Palmas de Gran Canaria, León, L'Hospitalet de Llobregat, Lleida, Madrid, Majadahonda, Málaga, San Cristobal De La Laguna, Santander, Sevilla, Valencia, Vigo, Zaragoza
Age
18 years and over
People
1,580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
Phase 3Taking people
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Where
Barcelona, Castello De La Plana, Elche, Girona, Las Palmas De Gran Canaria, Lleida, Madrid, Málaga, Murcia, Pamplona, Sevilla, Torrejón de Ardoz, Valencia, Vigo
Age
18 years to 90 years
People
507 worldwide
Run by
ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00
Phase 3Taking people
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Where
Barcelona, Málaga, Oviedo, Palma, Valencia
Age
18 years and over
People
480 worldwide
Run by
ArriVent BioPharma, Inc.
See details and how to joinNCT07185997
Phase 3Taking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Barcelona, Burgos, Elche, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Pamplona, Reus, Sevilla, Valencia
Age
18 years and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
Phase 2Taking people
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Where
Alicante, Badalona, Barcelona, Logroño, Málaga, Murcia, San Sebastián de los Reyes, Sevilla
Age
18 years and over
People
50 worldwide
Run by
Puma Biotechnology, Inc.
See details and how to joinNCT07465757 · EU 2026-525382-47-00
Phase 2/3Taking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
A Coruña, Badalona, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santiago De Compostela, Sevilla, Valencia
Age
18 years and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
Phase 1Taking people
Phase 1 Study of MK-1084 in KRAS mutant advanced solid tumors
Where
Barcelona, Madrid, Pamplona
Age
18 years and over
People
214 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05067283 · EU 2022-501563-40-00
Phase 1/2Taking people
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Where
Barcelona, Logroño, Madrid, Málaga, Sevilla
Age
18 years and over
People
345 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00
Phase 1/2Taking people
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Where
L'Hospitalet de Llobregat, Pozuelo de Alarcón
Age
18 years and over
People
450 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165070 · EU 2023-506932-33-00
No phaseTaking people
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
1,065 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04165798
Phase 3Taking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Alcorcón, Ávila, Barcelona, Fuenlabrada, Jaén, Las Palmas de Gran Canaria, Madrid, Valencia
Age
18 years and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
Phase 1/2Taking people
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Logroño, Madrid, Málaga, Pamplona, Sevilla
Age
18 years and over
People
364 worldwide
Run by
Synthekine
See details and how to joinNCT05098132 · EU 2025-522632-14-00
Phase 3Taking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Santiago de Compostela, Sevilla
Age
18 years and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Lleida, Madrid, Majadahonda, Sevilla
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Logrono
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 1Taking people
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
404 worldwide
Run by
Astellas Pharma Inc
See details and how to joinNCT07094204 · EU 2025-522082-29-00